{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:52:34Z","timestamp":1784735554104,"version":"3.55.0"},"reference-count":132,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>(1) Chronic heart failure (CHF) is a typical component of the polymorbid profile of an elderly patient. The aim of this systematic review was to search for data from pharmacokinetic (PK) studies of any drugs in patients with CHF to systematize information on changes in PK parameters depending on the physicochemical properties (PCPs) of the drug and route of its administration. (2) A systematic review of PK studies in patients with CHF was performed using Elibrary.ru, United States National Library of Medicine (PubMed), China National Knowledge Infrastructure (CNKI), and Directory of Open Access Journals (DOAJ). The final number of included articles was 106. A descriptive and correlation analysis of PK data and PCPs of drugs included in the study was carried out. Inclusion criteria: PK study, available PK parameters, demographic data, and diagnosed CHF. Risk of bias was assessed using ROBINS-I. (3) Evaluation of correlations between PCPs of drugs and their PK revealed a link between (i) plasma protein binding (PPB) and volume of distribution for lipophilic drugs; (ii) PCPs, half-life, and clearance for drugs with high PPB; and (iii) PPB and clearance for hydrophilic and amphiphilic drugs. (4) Hypoalbuminemia associated with CHF may lead to an increased volume of distribution of lipophilic drugs; lipophilic drugs used in CHF patients may be associated with prolongation of the half-life period and reduction in clearance; highly protein-bound drugs may manifest with reduced clearance. PK characteristics identified in this review should guide modifications to dosing regimens in CHF patients receiving medications from different groups.<\/jats:p>","DOI":"10.3390\/ijms26199495","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:38:55Z","timestamp":1759246735000},"page":"9495","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-2169","authenticated-orcid":false,"given":"Olga","family":"Butranova","sequence":"first","affiliation":[{"name":"Department of General and Clinical Pharmacology, Peoples\u2019 Friendship University of Russia Named After Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6348-6867","authenticated-orcid":false,"given":"Sergey","family":"Zyryanov","sequence":"additional","affiliation":[{"name":"Department of General and Clinical Pharmacology, Peoples\u2019 Friendship University of Russia Named After Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"},{"name":"Moscow City Health Department, City Clinical Hospital No. 24, State Budgetary Institution of Healthcare of the City of Moscow, Pistzovaya Str. 10, 127015 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Kustov","sequence":"additional","affiliation":[{"name":"Department of General and Clinical Pharmacology, Peoples\u2019 Friendship University of Russia Named After Patrice Lumumba (RUDN), 6 Miklukho-Maklaya St., 117198 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ehaa946.0960","DOI":"10.1093\/ehjci\/ehaa946.0960","article-title":"A population-based analysis in 375,233 cases of heart failure stages A, B and C. Real world epidemiology of prevalence and temporal trends in South-European populations","volume":"41","author":"Jimenez","year":"2020","journal-title":"Eur. Hear. J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tiller, D., Russ, M., Greiser, K.H., Nuding, S., Ebelt, H., Kluttig, A., Kors, J., Thiery, J., Bruegel, M., and Haerting, J. (2013). Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population\u2014The CARLA study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059225"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17116\/terarkh201587215-19","article-title":"Clinical and pathogenetic features of inflammatory and atrophic changes in the gastroduodenal zone in patients with varying severity of chronic heart failure associated with coronary artery disease","volume":"87","author":"Osadchiy","year":"2015","journal-title":"Ter. Arkhiv"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/psp4.12959","article-title":"Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole","volume":"12","author":"Yang","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lupu, V.V., Adam Raileanu, A., Mihai, C.M., Morariu, I.D., Lupu, A., Starcea, I.M., Frasinariu, O.E., Mocanu, A., Dragan, F., and Fotea, S. (2023). The Implication of the Gut Microbiome in Heart Failure. Cells, 12.","DOI":"10.3390\/cells12081158"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cicchinelli, S., Gemma, S., Pignataro, G., Piccioni, A., Ojetti, V., Gasbarrini, A., Franceschi, F., and Candelli, M. (2024). Intestinal Fibrogenesis in Inflammatory Bowel Diseases: Exploring the Potential Role of Gut Microbiota Metabolites as Modulators. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040490"},{"key":"ref_8","first-page":"e37377","article-title":"The Usefulness of Bioelectrical Impedance as a Marker of Fluid Status in Patients With Congestive Heart Failure: A Systematic Review and Meta-Analysis","volume":"15","author":"Hanna","year":"2023","journal-title":"Cureus"},{"key":"ref_9","first-page":"e58766","article-title":"Congestive Hepatopathy: A Review of the Literature","volume":"16","author":"Haddadin","year":"2024","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Berezin, A.A., Obradovic, Z., Berezina, T.A., Boxhammer, E., Lichtenauer, M., and Berezin, A.E. (2023). Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines. Antioxidants, 12.","DOI":"10.3390\/antiox12020516"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nakashima, M., Nakamura, K., Nishihara, T., Ichikawa, K., Nakayama, R., Takaya, Y., Toh, N., Akagi, S., Miyoshi, T., and Akagi, T. (2023). Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. Nutrients, 15.","DOI":"10.3390\/nu15030748"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Goliopoulou, A., Theofilis, P., Oikonomou, E., Anastasiou, A., Pantelidis, P., Gounaridi, M.I., Zakynthinos, G., Katsarou, O., Kassi, E., and Lambadiari, V. (2023). Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814292"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138920008783571792","article-title":"Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure","volume":"9","author":"Zordoky","year":"2008","journal-title":"Curr Drug Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.23876\/j.krcp.22.224","article-title":"How should we treat acute kidney injury caused by renal congestion?","volume":"42","author":"Abe","year":"2023","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2016.09.015","article-title":"Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure","volume":"224","author":"Lainscak","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_16","unstructured":"(2023, August 24). Checklist Based on the Recommendations of PRISMA 2020. (In Russian)."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/0009-9236(95)90022-5","article-title":"Fosinopril: Pharmacokinetics and pharmacodynamics in congestive heart failure","volume":"58","author":"Kostis","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.1989.tb05351.x","article-title":"The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure","volume":"27","author":"Till","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.2042-7158.1987.tb03130.x","article-title":"Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure","volume":"39","author":"Gautam","year":"1987","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151C","DOI":"10.1016\/0002-9149(92)91378-H","article-title":"Pharmacokinetic profiles of single and repeat doses of lisinopril and enalapril in congestive heart failure","volume":"70","author":"Johnston","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1253\/jcj.54.12_1497","article-title":"Effect of captopril on congestive heart failure","volume":"54","author":"Nishida","year":"1990","journal-title":"Jpn. Circ. J."},{"key":"ref_22","first-page":"2001","article-title":"The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure","volume":"6","author":"Miyagawa","year":"1990","journal-title":"Rinsho Iyaku"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00005344-198507000-00023","article-title":"Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension","volume":"7","author":"Schwartz","year":"1985","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.0306-5251.2001.01410.x","article-title":"Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients","volume":"52","author":"Bellissant","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00005344-199004000-00002","article-title":"Systemic and regional hemodynamic effects of perindopril in congestive heart failure","volume":"15","author":"Thuillez","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_26","first-page":"299","article-title":"Acute hemodynamic effect of quinapril on chronic heart failure","volume":"11","author":"Kimata","year":"1995","journal-title":"Rinsho Iyaku"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1994.tb04334.x","article-title":"Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure","volume":"38","author":"Squire","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2125.1994.tb04280.x","article-title":"The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure","volume":"37","author":"Begg","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00005344-199312002-00008","article-title":"Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure","volume":"22","author":"Heintz","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.2042-7158.1991.tb03498.x","article-title":"Initial and steady state pharmacokinetics of cilazapril in congestive cardiac failure","volume":"43","author":"Wiseman","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/00912700122012869","article-title":"Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure","volume":"41","author":"Kostis","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0735-1097(86)80235-2","article-title":"Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure","volume":"7","author":"Kessler","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/j.1552-4604.1996.tb04149.x","article-title":"Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy","volume":"36","author":"Tisdale","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.1980.10","article-title":"Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction","volume":"27","author":"Graffner","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.1985.tb02666.x","article-title":"Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure","volume":"19","author":"MacMahon","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/clpt.1983.221","article-title":"Tocainide kinetics in congestive heart failure","volume":"34","author":"Mohiuddin","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","first-page":"2135","article-title":"Pharmacokinetics and pharmacodynamics of SUN 1165, a novel antiarrhythmic agent, after administration of a single oral dose","volume":"10","author":"Yokota","year":"1989","journal-title":"Ther. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003495-198700343-00009","article-title":"Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure","volume":"34","author":"Rehnqvist","year":"1987","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ki.1984.153","article-title":"Bumetanide and furosemide in heart failure","volume":"26","author":"Brater","year":"1984","journal-title":"Kidney Int."},{"key":"ref_40","first-page":"123","article-title":"Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure","volume":"25","author":"Chaturvedi","year":"1987","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-102-3-314","article-title":"Furosemide absorption altered in decompensated congestive heart failure","volume":"102","author":"Vasko","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/j.1552-4604.1996.tb04196.x","article-title":"The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure","volume":"36","author":"Carlton","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0002-9343(98)00111-9","article-title":"The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure","volume":"104","author":"Gottlieb","year":"1998","journal-title":"Am. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","article-title":"Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure","volume":"57","author":"Vargo","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00561400","article-title":"Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure","volume":"12","author":"Andreasen","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00005344-199305000-00022","article-title":"Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure","volume":"21","author":"Gupta","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0090-9556(25)08801-4","article-title":"Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). I: Single dose stusy","volume":"20","author":"Gupta","year":"1992","journal-title":"Drug Metab Dispos."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/cpt1974162322","article-title":"Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure","volume":"16","author":"Tilstone","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00543318","article-title":"Decreased renal clearance of digoxin in chronic congestive heart failure","volume":"28","author":"Naafs","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/j.1552-4604.1981.tb01760.x","article-title":"Digoxin pharmacokinetics in congestive heart failure","volume":"21","author":"Applefeld","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/j.1552-4604.1996.tb04195.x","article-title":"The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure","volume":"36","author":"Carlton","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","first-page":"155","article-title":"The effect of carvedilol on plasma digoxin concentration in patients with chronic heart failure","volume":"24","author":"Machida","year":"2007","journal-title":"Jpn. J. Ther. Drug Monit."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/00003088-200140100-00005","article-title":"Population pharmacokinetics of digoxin in Japanese patients: A 2-compartment pharmacokinetic model","volume":"40","author":"Yukawa","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1552-4604.1997.tb04766.x","article-title":"Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: An update","volume":"37","author":"Yukawa","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"ref_55","first-page":"III145","article-title":"Pharmacokinetics of the bipyridines amrinone and milrinone","volume":"73","author":"Edelson","year":"1986","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0002-9149(85)91036-7","article-title":"Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure","volume":"56","author":"Benotti","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s001340051322","article-title":"Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration","volume":"26","author":"Taniguchi","year":"2000","journal-title":"Intensive Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000176828","article-title":"Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure","volume":"86","author":"Seino","year":"1995","journal-title":"Cardiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1177\/0091270002042012011","article-title":"The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and\/or concomitant hepatic impairment","volume":"42","author":"Tammara","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"ref_60","first-page":"1103","article-title":"Clinical effects and pharmacokinetics of alpha-human atrial natriuretic peptide (SUN 4936; carperitide) in patients with acute heart failure","volume":"21","author":"Obata","year":"1993","journal-title":"Jpn. Pharmacol. Ther."},{"key":"ref_61","first-page":"491","article-title":"Pharmacokinetics and pharmacodynamics of molsidomine in patients with liver dysfunction due to congestive heart failure","volume":"30","author":"Huber","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.clinthera.2009.07.011","article-title":"Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)\/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study","volume":"31","author":"Mao","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00005344-198307000-00027","article-title":"Reduced distribution and clearance of acetaminophen in patients with congestive heart failure","volume":"5","author":"Ochs","year":"1983","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2125.2001.01279.x","article-title":"The pharmacokinetics of etanercept in patients with heart failure","volume":"51","author":"Soran","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_65","first-page":"H56","article-title":"Comparison of norepinephrine and isoproterenol clearance in congestive heart failure","volume":"263","author":"Leuenberger","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1253\/circj.CJ-21-0430","article-title":"OPC-61815 Investigators. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure\u2014A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial","volume":"86","author":"Sato","year":"2022","journal-title":"Circ. J."},{"key":"ref_67","first-page":"3","article-title":"Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology","volume":"56","author":"Wilson","year":"1987","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_68","first-page":"105","article-title":"Ibopamine kinetics after a single oral dose in patients with congestive heart failure","volume":"26","author":"Azzollini","year":"1988","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000175026","article-title":"Hemodynamic effects and pharmacokinetics of longterm therapy with ibopamine in patients with chronic heart failure","volume":"80","author":"Itoh","year":"1992","journal-title":"Cardiology"},{"key":"ref_70","first-page":"544","article-title":"Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure","volume":"26","author":"Azzollini","year":"1988","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/0091270011433435","article-title":"Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation","volume":"53","author":"Nisi","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/00912700022009576","article-title":"Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure","volume":"40","author":"Tenero","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39L","DOI":"10.1016\/j.amjcard.2006.07.018","article-title":"Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction","volume":"98","author":"Packer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1248\/bpb.31.976","article-title":"Pharmacokinetics of R- and S-Carvedilol in routinely treated Japanese patients with heart failure","volume":"31","author":"Horiuchi","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1248\/bpb.33.1378","article-title":"Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure","volume":"33","author":"Saito","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"ref_76","first-page":"1662","article-title":"Pharmacokinetics of candesartan cilexetil (TCV-116) in patients with chronic heart failure","volume":"45","author":"Abo","year":"1996","journal-title":"J. N. Remedies Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/009127000104100902","article-title":"The pharmacokinetics and pharmacodynamics of irbesartan in heart failure","volume":"41","author":"Kostis","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/j.1552-4604.1998.tb05790.x","article-title":"Pharmacokinetics of intravenous and oral losartan in patients with heart failure","volume":"38","author":"Lo","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF01061722","article-title":"Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. J","volume":"12","author":"Lima","year":"1984","journal-title":"Pharmacokinet. Biopharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1600-0773.1985.tb01290.x","article-title":"Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure","volume":"56","author":"Bonde","year":"1985","journal-title":"Acta Pharmacol. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJM197403282901303","article-title":"Quinidine elimination in patients with congestive heart failure or poor renal function","volume":"290","author":"Kessler","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/bmj.1.6015.939","article-title":"Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure","volume":"1","author":"Prescott","year":"1976","journal-title":"Br. Med. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-78-4-499","article-title":"Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans","volume":"78","author":"Thomson","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1981.00340010039011","article-title":"Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations","volume":"141","author":"Sawyer","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1248\/bpb.29.2267","article-title":"Effect of congestive heart failure on mexiletine pharmacokinetics in a Japanese population","volume":"29","author":"Kobayashi","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/j.1552-4604.1996.tb04241.x","article-title":"Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function","volume":"36","author":"Vadiei","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1592\/phco.28.12.1461","article-title":"Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction","volume":"28","author":"Tisdale","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2125.1989.tb03504.x","article-title":"Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure","volume":"28","author":"Dunselman","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_89","first-page":"1008","article-title":"Nifedipine pharmacodynamics and pharmacokinetics in treatment of congestive heart failure","volume":"103","author":"Chen","year":"1990","journal-title":"Chin. Med. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2125.1997.t01-1-00586.x","article-title":"An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure","volume":"44","author":"Muller","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_91","first-page":"901","article-title":"Clinicopharmacological study of nicardipine hydrochloride: Pharmacokinetics and hemodynamics after intravenous infusion in patients with acute heart failure","volume":"23","author":"Hirasawa","year":"1995","journal-title":"Jpn. Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2362.1989.tb00245.x","article-title":"Efficacy and pharmacokinetics of piretanide in patients with congestive heart failure","volume":"19","author":"Marone","year":"1989","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0002-8703(91)90522-J","article-title":"Clinical pharmacology of intravenous enoximone: Pharmacodynamics and pharmacokinetics in patients with heart failure","volume":"122","author":"Smith","year":"1991","journal-title":"Am. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/j.1552-4604.1991.tb03763.x","article-title":"Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure","volume":"31","author":"Ruder","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/j.1552-4604.1987.tb03083.x","article-title":"Oral enoximone pharmacokinetics in patients with congestive heart failure","volume":"27","author":"Lima","year":"1987","journal-title":"J. Clin. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/00005344-199506261-00008","article-title":"Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure","volume":"26","author":"Sandell","year":"1995","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5414\/CPP41365","article-title":"Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure","volume":"41","author":"Poder","year":"2003","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2125.2003.02043.x","article-title":"Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan","volume":"57","author":"Antila","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0167-5273(03)00030-5","article-title":"Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure","volume":"91","author":"Kieback","year":"2003","journal-title":"Int. J. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11317590-000000000-00000","article-title":"Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure","volume":"49","author":"Mueck","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/clpt.1992.177","article-title":"Clinical pharmacology of nicorandil in patients with congestive heart failure","volume":"52","author":"Tice","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cpt1978245537","article-title":"Dobutamine pharmacokinetics in severe heart failure","volume":"24","author":"Kates","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2125.1990.tb03680.x","article-title":"The pharmacokinetics of midazolam in patients with congestive heart failure","volume":"29","author":"Patel","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/BF01496473","article-title":"Theophylline elimination in congestive heart failure","volume":"61","author":"Kuntz","year":"1983","journal-title":"Klin. Wochenschr."},{"key":"ref_105","first-page":"274","article-title":"Theophylline clearance in obese patients in relation to smoking and congestive heart failure. Drug Intell","volume":"17","author":"Slaughter","year":"1983","journal-title":"Clin. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/106002809402800319","article-title":"Theophylline disposition in Korean patients with congestive heart failure","volume":"28","author":"Jeong","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/1043-6618(90)90846-6","article-title":"The effect of sex and cardiac failure on the pharmacokinetics of a slow-release theophylline formulation in the elderly","volume":"22","author":"Cuzzolin","year":"1990","journal-title":"Pharmacol. Res."},{"key":"ref_108","first-page":"936","article-title":"Effect of congestive heart failure on theophylline disposition","volume":"9","author":"Ueno","year":"1990","journal-title":"Clin. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure","volume":"30","author":"Gheorghiade","year":"2011","journal-title":"J. Heart Lung Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0009-9236(95)90223-6","article-title":"Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing","volume":"57","author":"Chu","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00316479","article-title":"Pharmacokinetics of flosequinan in elderly patients with chronic congestive heart failure","volume":"44","author":"Sakai","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s002280050110","article-title":"Pharmacokinetics of flosequinan in patients with heart failure","volume":"50","author":"Nicholls","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.2009.03587.x","article-title":"Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure","volume":"69","author":"Orlando","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00005344-198103000-00011","article-title":"Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure","volume":"3","author":"Silke","year":"1981","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1988.186","article-title":"Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure","volume":"44","author":"Cook","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.1111\/j.1365-2125.1989.tb03491.x","article-title":"A pharmacokinetic study of cilazapril in patients with congestive heart failure","volume":"27","author":"Rosenthal","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/j.1552-4604.1986.tb03519.x","article-title":"Dose- and timedependent binding and kinetics of pindolol in patients with congestive heart failure","volume":"26","author":"Lima","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/j.1552-4604.1987.tb02182.x","article-title":"Effect of congestive heart failure on the pharmacokinetics of cibenzoline","volume":"27","author":"Massarella","year":"1987","journal-title":"J. Clin. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/clpt.1985.220","article-title":"Determinants of systemic availability of oral hydralazine in heart failure","volume":"38","author":"Crawford","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2125.2008.03257.x","article-title":"Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure","volume":"66","author":"Iida","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.CIR.62.1.160","article-title":"Pharmacokinetic hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure","volume":"62","author":"Armstrong","year":"1980","journal-title":"Circulation"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00544357","article-title":"Pharmacokinetic and plasma-concentration-effect relationships of prenalterol in cardiac failure","volume":"28","author":"Sainsbury","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF00609892","article-title":"Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure","volume":"24","author":"Dahlstrom","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"226","DOI":"10.23736\/S0026-4806.20.06244-8","article-title":"Hypoalbuminemia as a marker of protein metabolism disarrangement in patients with stable chronic heart failure","volume":"111","author":"Pasini","year":"2020","journal-title":"Minerva Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-016-2086-y","article-title":"Drug Distribution Part 2. Predicting Volume of Distribution from Plasma Protein Binding and Membrane Partitioning","volume":"34","author":"Korzekwa","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acsmedchemlett.8b00018","article-title":"Strategy for Extending Half-life in Drug Design and Its Significance","volume":"9","author":"Gunaydin","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"bvad114.626","DOI":"10.1210\/jendso\/bvad114.626","article-title":"FRI113 Increased Body Fat Is Associated With Heart Failure Of Ischemic Cause","volume":"7","author":"Bandeira","year":"2023","journal-title":"J. Endocr. Soc"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1111\/bcp.14735","article-title":"Effect of lipophilicity on drug distribution and elimination: Influence of obesity","volume":"87","author":"Bruno","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Jongmans, C., Muller, A.E., Van Den Broek, P., Cruz De Almeida, B.D.M., Van Den Berg, C., Van Oldenrijk, J., Bos, P.K., and Koch, B.C.P. (2022). An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.900551"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dezanet, C., Kempf, J., Mingeot-Leclercq, M.-P., and D\u00e9cout, J.-L. (2020). Amphiphilic Aminoglycosides as Medicinal Agents. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197411"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Butranova, O.I., Ushkalova, E.A., Zyryanov, S.K., Chenkurov, M.S., and Baybulatova, E.A. (2023). Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061633"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Butranova, O.I., Ushkalova, E.A., Zyryanov, S.K., and Chenkurov, M.S. (2023). Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030940"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9495\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:44:11Z","timestamp":1759247051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":132,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199495"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199495","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}